JSC PHARMSTANDARD REPORTS 2008 AUDITED FINANCIAL RESULTS AND 1Q 2009 SALES RESULTS

28.04.2009

Moscow, 28 April, 2009 – JSC Pharmstandard (LSE: PHST LI, RTS: PHST RU) published its audited 2008 financial results and sales results for 1Q 2009. Gross profit for the year ended 31 December 2008 amounted to RUR 8,758 million (2007: RUR 6,852 million) representing 28% increase. Sales in 1Q 2009 increased by 38%.

2008 audited Financial Results

Key Highlights

 

·         Revenue growth +26%; total revenue RUR 14,336 million

·         Gross profit growth +28%; gross profit RUR 8,759 million or 61% of sales

·         EBITDA[1] growth +24%; EBIDTA RUR 6,049 million or 42% of sales

·         Net profit growth + 7%; net profit RUR 3,503 million or 24% of sales

Revenue

The total revenue in 2008 amounted to RUR 14,335.9 million, which is by 26% more than in 2007 (RUR 11,371.3 million). The sales of pharmaceutical products amount 92.5% of total sales while the sales of medical equipment account for the remaining 7.5%.

Pharmaceutical Products

Revenue from pharmaceutical products was RUR 13,260 million, compared to RUR 9,763 million in the prior year’s period, an increase of RUR 3,498 million or 36%.

The sales of OTC products grew by RUR 2,033.5 million or by 24% – from RUR 8,519.9 million in 2007 to RUR 10,553.4 million in 2008. This increase was achieved largely due to implementation of an active promotion strategy.  The main contribution can be attributed to the following products: Arbidol®, Terpincod®, Pentalgin® and Codelac®. The sales of Afobazol® over the 5 months of 2008 (the trademark, was acquired by Pharmstandard in 2008) achieved an impressive result of RUR 217.5 million. 

The sales of prescription products (Rx) increased by RUR 1,449.4 million or by 122% – from RUR 1,188.2 million in 2007 to RUR 2,637.6 million in 2008. This increase was largely achieved due to the sales of Mildronate® (2008: RUR 1149 million). The organic sales growth in the Rx products segment (excluding Mildronate®) was equal to RUR 300.3 million or 25.2%. The organic growth of Rx products sales volume was materially influenced by the sales of Phosphogliv®, Cyclodol® and Biosulin®.

Medical Equipment & Disposables

In 2008, the sales of medical equipment and disposables dropped by RUR 553.0 million or by 33% and amounted to RUR 1,075.6 million against RUR 1,608.7 million in 2007. This decrease, however, cannot be interpreted as critical, since the high sales figures of 2007 were achieved mainly due to the fact that the Company was awarded a major government contract for sterilizers from the Directorate of the Federal Agency for the RF State Reserves. No similar tenders were held in 2008. Therefore, the analysis of the medical equipment segment trend over the period of 2007-2008 excluding the figures related to the above tender shows that the absolute decrease in the sales of medical equipment was equal to RUR 79.1 million or 7%.

This trend is mainly a result of the global recession, which lessened effective demand for high-priced equipment.

Cost of Sales

In 2008, the cost of goods sold by the Company increased by RUR 1,057.8 million or by 23% as compared to 2007 and amounted to RUR 5,577.5 million against RUR 4,519.7 million in 2007. In 2008, percentage of cost of sales in relation to total sales dropped to 38.9% against 39.7% in 2007 due to a considerable reduction of production overheads (by 10% or by RUR 80.6 million) achieved through the transfer of Masterlek products manufacturing to Pharmstandard own production facilities.

Gross Profit

The Company recorded a RUR 1,906.8 million or a 28% gross profit growth – from RUR 6,851.6 million in 2007 to RUR 8,758.4 million in 2008. Gross profit, as a percentage of revenue, achieved 61% comparing to 60% in 2007.

The main gross profit growth factors include (i) synergy effect achieved from the transfer of Arbidol®, Flukostat® and Phosphogliv® production to Pharmstandard own production facilities; and (ii) increased sales of highly cost-effective products.

Operating Expenses

Operating expenses increased by RUR 926.5 million or by 42% – from RUR 2,196.6 million in 2007 to RUR 3,123.1 million in 2008. The operating expenses to sales ratio increased from 19.3% in 2007 to 21.8% in 2008.

In 2008, operating expenses related to Sales and Distribution (S&D) increased by RUR 840.8 million (52%) and amounted to RUR 2,466.8 million against RUR 1,626.0 million in 2007, i.e. comprised 17.2% and 14.3%  of total sales, respectively. This relative increase occurred due to the allowances for impairment of receivables of one of the Company’s distributors CJSC Genesis in the amount of RUR 476.1 million in connection with the initiation of a bankruptcy procedure against that distributor.

In 2008, General and Administrative expenses (G&A) increased by RUR 85.7 million or by 15% and amounted to RUR 656.2 million against RUR 570.5 million in 2007. Labour costs are the major item of general and administrative expenses (61.4% of G&A).  As a percentage of sales, G&A expenses slightly decrease to 4.6% from 5.0%.


EBITDA

EBITDA increased RUR 1,167 million or 24% to RUR 6,049 million in 2008 from RUR 4,882 million in 2007.  EBITDA margin equals 42,3% which is  in small decrease  in comparison with EBITDA margin 42,9% in 2007.

Other Expenses, net and Interest Expenses, net

Other expenses in 2008 amounted to RUR 715.2 million or 5% of the total sales. Foreign exchange loss equal to RUR 524.8 million was the most significant item (3.7% of the total sales). The loss was caused by a considerable increase in the US dollar-rouble exchange rate in the fourth quarter 2008, resulting from the global financial crisis. An additional component of the other expenses item in 2008 was impairment of Afobazol® trademark amounting to RUR 140.5 million as of 31 December 2008. This impairment mainly resulted from increase of the discount rate applied in the trade mark valuation model from 13% to 18.1% for the first 10 years of the trademark’s useful economic life and declining thereafter. This increase in discount rate was a direct result of the current global financial crisis.

 

At the same time, this item shows the positive balance resulting from reimbursement of RUR 107.2 million promotional expenses primarily related to the Mildronate® Project.

In 2008, our interest expenses, net dropped by RUR 59 million or by 20% – from RUК 291.6  miion in 2007 to RUR 232.6 million in 2008 – due to the scheduled repayment of debts under the syndicated loan contract signed with the Citibank in December 2006. The contract stipulates full repayment of the debt in 2011.

Net Profit

In 2008, the Company’s net profit increased by RUR 239.9 million or by 7% and amounted to RUR 3,503.1 million against RUR 3,263.2 million in 2007, i.e. 24.4% and 28.7% to total sales, respectively. Net profit attributable to equity holders of the parent was RUR 3,504.0 million. Net loss attributable to minority shareholders was RUR 0.9 million.

 

Consolidated Balance Sheet at 31 December 2008
(in thousands of Russian Roubles)

 

 

n

 

 

2008

2007

ASSETS

 

 

 

Non-current assets

 

 

 

Property, plant and equipment

 

3,917,109

3,691,266

Intangible assets

 

6,347,141

4,468,477

Long-term financial assets at fair value through profit or loss

 

-

245,398

 

 

10,264,250

8,405,141

Current assets

 

 

 

Inventories

 

2,484,910

1,760,195

Trade receivables

 

4,761,359

4,176,200

VAT recoverable

 

326,208

358,767

Prepayments

 

73,544

130,479

Short-term financial assets at fair value through profit or loss

 

113,995

111,899

Cash and cash equivalents

 

186,066

192,589

 

 

7,946,082

6,730,129

Non-current assets classified as held for sale

 

-

158,855

 

 

 

 

Total assets

 

18,210,332

15,294,125

 

 

 

 

EQUITY AND LIABILITIES

 

 

 

Equity attributable to equity holders of the parent

 

 

 

Share capital

 

37,793

37,793

Retained earnings

 

12,413,396

9,004,021

 

 

12,451,189

9,041,814

Minority interest

 

163,203

560,879

Total equity

 

12,614,392

9,602,693

 

 

 

 

Non-current liabilities

 

 

 

Long-term borrowings and loans

 

760,512

1,954,576

Deferred tax liability

 

739,186

1,047,799

Derivative financial instruments

 

89,087

44,598

Other non-current liabilities

 

34,048

36,826

 

 

1,622,833

3,083,799

 

 

 

 

Current liabilities

 

 

 

Trade and other payables and accruals

 

1,707,544

1,046,520

Current portion of long-term borrowings

 

1,582,722

1,310,374

Income tax payable

 

144,292

37,934

Other taxes payable

 

339,307

212,806

Bank overdraft

 

199,242

-

 

 

3,973,107

2,607,633

 

 

 

 

Total liabilities

 

5,595,940

5,691,432

 

 

 

 

Total equity and liabilities

 

18,210,332

15,294,125

 

 

 

 

 

 

Consolidated Income Statement 
For the Year Ended 31 December 2008
(in thousands of Russian Roubles)

 

 

 

2008

2007

 

 

 

 

Revenue

 

14,335,867

11,371,345

Cost of sales

 

(5,577,468)

(4,519,749)

 

 

 

 

Gross profit

 

8,758,399

6,851,596

 

 

 

 

Selling and distribution costs

 

(2,466,841)

(1,626,041)

General and administrative expenses

 

(656,248)

(570,519)

 

 

 

 

Other income

 

149,762

274,142

Other expenses

 

(864,963)

(315,591)

Financial income

 

22,569

28,729

Financial expense

 

(255,189)

(320,367)

 

 

 

 

Profit before income tax

 

4,687,489

4,321,949

 

 

 

 

Income tax expense

 

(1,184,381)

(1,058,709)

 

 

 

 

Profit for the year

 

3,503,108

3,263,240

 

 

 

 

Attributable to:

 

 

 

Equity holders of the Parent

 

3,504,046

3,227,895

Minority interests

 

(938)

35,345

 

 

 

 

 

 

3,503,108

3,263,240

Earnings per share (in Russian roubles)

 

 

 

- basic and diluted, for profit of the year attributable to equity holders of the parent

 

92.72

85.41

 

 

1Q 2009 Sales Results

According to unaudited report, Pharmstandard net sales in 1Q 2009 increased by 38% to RUR 4,553 million, which represents the increase of RUR 1,256 million in comparison with RUR 3,297 million in 1Q 2008. Pharmaceutical products and medical equipment sales contributed 97% and 3% of total sales, respectively.

In 1Q 2009 the Company’s sales of pharmaceutical products achieved RUR 4,445 million and increased by 45% compared to 1Q 2008. Pharmaceutical sales contributed between OTC and Rx as 80% and 20% respectively.

The sales of OTC products were RUR 3,548 million in 1Q 2009 and grew by 43% in comparison with prior-year period.  Key growth drivers in OTC segment were Arbidol®, Pentalgin®, Flukostat®, Complivit®.

The Company’s revenue from prescription (Rx) products amounted to RUR 878 million and increased by 52% compared with 1Q 2008.  Sales growth of Pharmstandard Rx products achieved RUR 480 million and increased by 60% compared to 1Q 2009. Key growth drivers  in Rx are Phosphogliv®, Cyclodol®, Azitroks® and Mildronate®.

In 1Q 2009 the Company reported revenues of RUR 108 million from its medical equipment business segment, which represents a 54% decline in comparison with 1Q 2008.


Sales structure – 1Q 2009, RUR million.


 

1Q 2009 (mln RUR)

1Q 2008 (mln RUR)

Difference (mln RUR)

Difference (%)

Pharmaceutical products

4 445

3 061

1 384

45%

OTC products

3 548

2 477

1 071

43%

Prescription products

878

576

302

52%

     Mildronat

398

277

121

44%

Other sales

19

8

11

133%

Medical equipment and disposables

108

236

-128

-54%

Total sales

4 553

3 297

1 256

38%


Conference Call

Pharmstandard is pleased invite the investment community to a results conference call with the management of the company followed by a Q&A session.


Tuesday, April 28, 2009

09:00 New York

14:00 London

17:00 Moscow

International Call-in Number:  +44 (0)20 7162 0025

US Call-in Number: +1 334 323 6201

We recommend that participants start dialling in 5-10 minutes prior to ensure a timely start to the conference call. Conference call participants can register in advance using the link below:
https://eventreg1.conferencing.com/webportal3/reg.html?Acc=387058&Conf=165949


Pharmstandard will be represented by:

Igor Krylov, CEO

Elena ArkhangelskayaCFO

Olga Mednikova, Sales & Marketing


Conference call presentation will be available on Tuesday, 28 April 2009 on Company’s web-site: http://www.pharmstd.ru/investors_en/investor/p2/

The conference call replay will be available through May 3, 2009.

International Replay Number: +44 (0) 20 7031 4064

US Toll Replay Number : +1 954 334 0342

Replay Access Code: 832737


Contacts:

JSC Pharmstandard
Anton Golubok
Tel: +7 495 970 0030 ext 2029
E-mail: ir@pharmstd.ru
www.pharmstd.ru



***

Pharmstandard is the leading Russian pharmaceutical company. According to Pharmexpert Marketing Research Centre, it holds the top position in the domestic pharmaceutical market retail segment and the second position among Russian pharmaceutical companies overall. Pharmstandard is the only Russian company among the top ten Russian pharmaceutical market operators.

Pharmstandard portfolio includes over 200 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer, etc. Over 90 products offered by Pharmstandard are included in the List of Vital Pharmaceutical Products.

Pharmstandard products are well known to Russian consumers. Among our market-leading brands are Arbidol ®, Complivit®, Pentalgin®, Flucostat®, Codelac®, Phosphogliv®, Amiksin® and Afobazol®. Arbidol® is the leading brand on the Russian pharmaceutical market. Its antiviral action has been studied in international research centers. Pentalgin® has been granted “BRAND #1 IN RUSSIA” award for 2008 in analgesics category. Afobazol® - new original selective anxiolytic for anxiety disorders treatment.

Pharmstandard have agreements with Grindex, Latvia on exclusive distribution and promotion of Mildronate® (cardio-vascular) and with Solvay Pharmaceuticals, France on production of IRS19® and Imudon® (immunomodulating).

In 2004–2008, we developed and introduced over 35 new pharmaceutical products. Our business priorities lie in the development of new product lines comprising genetically engineered medicines, vitamin and mineral complexes, cold relief preparations and medicines used in the treatment of cardiovascular, gastroenterological, neurological disorders and endocrinopathies. Currently, the Company is working on the development of new high-tech formulations in close cooperation with the leading Russian research centres.

Pharmstandard operates four pharmaceutical manufacturing facilities in Kursk, Ufa, Tomsk and Nizhny Novgorod and, with a production capacity of 1.3 billion packs per year. Six production lines of JSC «Pharmstandard-Leksredstva» meet GMP requirements. JSC «Pharmstandard-Leksredstva» is the first Russian pharmaceutical plant included in EudraGMP database. All plants meet Russian legislative requirements.

In addition to its pharmaceutical business, the Company also develops, manufactures, markets and sells medical equipment, such as sterilizing and distilling machines, and disposable medical products.

The Company has invested approximately RUR 3 billion in capital investments in its manufacturing facilities since 2004. Pharmstandard placed its shares on Russian Trading System (RTS) and GDRs on London Stock Exchange (LSE) during IPO in May 4, 2007. The current GDR to ordinary share ratio is 1:4. Augment Investments Limited controls 54.2% of share capital. Free float represents 45.8% of share capital (LSE – 27.5%, RTS – 18.3%).

www.pharmstd.ru



 



This press release does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of JSC Pharmstandard (the “Company”) or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity. No part of this press release, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.





[1] EBITDA is defined as profit for the accounting period before finance costs, income tax expense and depreciation and amortization and excluding foreign exchange gain or loss




 


Back Print out

Media Contacts



Marina Shurkina


Head of Administrative Division Pharmstandard JSC

+7 (495) 970 0032
pr@pharmstd.ru

5B, Likhachyovsky Proezd, Dolgoprudny, Moscow Region, 141701, Russia

+7 (495) 970 0030/32

16+

© 2007–2018

All rights reserved. JSC Pharmstandard.
Terms of use Disclosure of information.

ПРЕДУПРЕЖДЕНИЕ

Информация на сайте предназначена исключительно для медицинских работников.

Подтвердите, пожалуйста, являетесь ли Вы медицинским работником.

Если Вы не являетесь медицинским работником, пожалуйста, покиньте данный раздел сайта.


СОГЛАШЕНИЕ О ПОЛУЧЕНИИ ИНФОРМАЦИИ О РЕЦЕПТУРНЫХ ПРЕПАРАТАХ

1.На сайте представлена информация о рецептурных препаратах, их свойствах, способах применения и возможных противопоказаниях исключительно специалистам здравоохранения (лицам, имеющим высшее или среднее специальное медицинское образование).

2. Если Вы являетесь специалистом здравоохранения и хотите получить информацию с данного раздела сайта, Вам необходимо подтвердить ваш статус специалиста здравоохранения.

3. В случае если Вы не являетесь специалистом здравоохранения, но в нарушение настоящих условий подписываете данное соглашение, сайт Компании не несет ответственности за возможные отрицательные последствия, возникшие в результате самостоятельного использования Вами информации с сайта, без предварительной консультации со специалистом. Вы делаете это самостоятельно и осознанно, понимая, что применение рецептурных препаратов возможно только после предварительной консультации со специалистом здравоохранения.

4. Информация о рецептурных препаратах, представленная на данном разделе сайте, предназначена исключительно для ознакомления с препаратами и не является руководством для самостоятельной диагностики или лечения, и не служит в качестве медицинских советов или рекомендаций. Сайт не несет ответственности за возможный ущерб, нанесенный Вашему здоровью в случае самовольного лечения, проводимого на основании применения рецептурных препаратов (без предварительной консультации со специалистом). Настоящим я подтверждаю, что являюсь специалистом здравоохранения и подтверждаю своё согласие с тем, что применение рецептурных препаратов возможно только после предварительной консультации со специалистом.